BidaskClub lowered shares of Akcea Therapeutics (NASDAQ:AKCA) from a buy rating to a hold rating in a research note issued to investors on Wednesday.
Several other brokerages have also issued reports on AKCA. Cowen reaffirmed a buy rating on shares of Akcea Therapeutics in a research note on Tuesday, October 31st. Zacks Investment Research raised Akcea Therapeutics from a hold rating to a buy rating and set a $19.00 target price for the company in a research note on Tuesday, January 2nd. Finally, Stifel Nicolaus reaffirmed a buy rating and issued a $20.00 target price (up previously from $19.00) on shares of Akcea Therapeutics in a research note on Tuesday, November 7th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company has an average rating of Buy and a consensus target price of $22.75.
Shares of Akcea Therapeutics (NASDAQ:AKCA) opened at $21.37 on Wednesday. Akcea Therapeutics has a 52 week low of $8.10 and a 52 week high of $31.23.
A number of hedge funds have recently made changes to their positions in AKCA. Legal & General Group Plc bought a new stake in Akcea Therapeutics in the third quarter valued at approximately $111,000. Strs Ohio bought a new stake in Akcea Therapeutics in the third quarter valued at approximately $118,000. SG Americas Securities LLC bought a new stake in Akcea Therapeutics in the fourth quarter valued at approximately $121,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Akcea Therapeutics in the third quarter valued at approximately $180,000. Finally, MetLife Investment Advisors LLC bought a new stake in Akcea Therapeutics in the fourth quarter valued at approximately $199,000. Hedge funds and other institutional investors own 28.29% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This article was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another website, it was illegally stolen and republished in violation of international copyright and trademark laws. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/02/22/akcea-therapeutics-akca-downgraded-to-hold-at-bidaskclub.html.
About Akcea Therapeutics
Akcea Therapeutics, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company’s drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc (Ionis).
Receive News & Ratings for Akcea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akcea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.